OTCMKTS:AGYTF

Allergy Therapeutics (AGYTF) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.02
$0.02
50-Day Range
N/A
52-Week Range
$0.17
$0.19
Volume
N/A
Average Volume
N/A
Market Capitalization
$13.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AGYTF stock logo

About Allergy Therapeutics Stock (OTCMKTS:AGYTF)

Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

AGYTF Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
REDCON1 ENERGY LAUNCHES AT CIRCLE K STORES
Webinar: AT&S introduces the future of computing
LEGO's AT-AT set gets a big price cut
See More Headlines
Receive AGYTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/25/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Private households
Sub-Industry
N/A
Current Symbol
OTCMKTS:AGYTF
Previous Symbol
NASDAQ:AGYTF
CIK
N/A
Fax
N/A
Employees
600
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$73.41 million
Book Value
($0.01) per share

Miscellaneous

Free Float
N/A
Market Cap
$13.78 million
Optionable
Not Optionable
Beta
516.99
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Manuel Llobet (Age 57)
    CEO & Exec. Director
    Comp: $683.78k
  • Mr. Nicolas Alexander Ulrich Wykeman (Age 56)
    CFO & Exec. Director
    Comp: $392.3k
  • Ms. Beverly Lees
    Group Operations Director
  • Dr. Murray Skinner
    Chief Scientific Officer
  • Mr. Santiago Puig
    Bus. Devel. Director
  • Ms. Sue Baker
    Head of HR
  • Simon Piggott
    Head of Clinical Science
  • Alan Bullimore
    Head of Communication & Market Devel.
  • Mr. Russell Picket
    Group Financial Controller
  • Sara Goldsbrough
    Company Sec.

This page (OTCMKTS:AGYTF) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners